The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary Involvement

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F24%3A73622534" target="_blank" >RIV/61989592:15110/24:73622534 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/24:00138636 RIV/00216305:26220/24:PU150581 RIV/65269705:_____/24:00079463 RIV/00098892:_____/24:10158607

Result on the web

<a href="https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7" target="_blank" >https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s41479-023-00123-7" target="_blank" >10.1186/s41479-023-00123-7</a>

Result language

angličtina

Original language name

The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary Involvement

Original language description

Rationale Persistent respiratory symptoms following Coronavirus Disease 2019 (COVID-19) are associated with residual radiological changes in lung parenchyma, with a risk of development into lung fibrosis, and with impaired pulmonary function. Previous studies hinted at the possible efficacy of corticosteroids (CS) in facilitating the resolution of post-COVID residual changes in the lungs, but the available data is limited.Aim To evaluate the effects of CS treatment in post-COVID respiratory syndrome patients.Patients and methods Post-COVID patients were recruited into a prospective single-center observational study and scheduled for an initial (V1) and follow-up visit (V2) at the Department of Respiratory Medicine and Tuberculosis, University Hospital Olomouc, comprising of pulmonary function testing, chest x-ray, and complex clinical examination. The decision to administer CS or maintain watchful waiting (WW) was in line with Czech national guidelines.Results The study involved 2729 COVID-19 survivors (45.7% male; mean age: 54.6). From 2026 patients with complete V1 data, 131 patients were indicated for CS therapy. These patients showed significantly worse radiological and functional impairment at V1. Mean initial dose was 27.6 mg (SD +- 10,64), and the mean duration of CS therapy was 13.3 weeks (SD +- 10,06). Following therapy, significantly better improvement of static lung volumes and transfer factor for carbon monoxide (DLCO), and significantly better rates of good or complete radiological and subjectiveimprovement were observed in the CS group compared to controls with available follow-up data (n = 894).Conclusion Better improvement of pulmonary function, radiological findings and subjective symptoms were observed in patients CS compared to watchful waiting. Our findings suggest that glucocorticoid therapy could benefit selected patients with persistent dyspnea, significant radiological changes, and decreased DLCO.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30203 - Respiratory systems

Project

<a href="/en/project/NU22-A-105" target="_blank" >NU22-A-105: Predicitve biomarkers of therapeutic response on COVID-19 therapy</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pneumonia

ISSN

2200-6133

e-ISSN

2200-6133

Volume of the periodical

16

Issue of the periodical within the volume

1

Country of publishing house

AU - AUSTRALIA

Number of pages

10

Pages from-to

2

UT code for WoS article

001156289200001

EID of the result in the Scopus database

—